ReCode Therapeutics Announces Participation in Upcoming October Investor Conferences

Menlo Park, Calif. and Dallas, Texas September 28, 2021ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will participate in three upcoming virtual investor conferences in October:

  • Chardan 5th Annual Genetic Medicines Conference
    Format: Presentation
    Date: Monday, October 4, 2021
    Time: 1:30 p.m. ET

    Format: Panel titled “RNA: RNA-based Targeted Delivery Approaches”
    Date: Tuesday, October 5, 2021
    Time: 3:00 p.m. ET

  • Piper Sandler Lung Day
    Format: Fireside Chat
    Date: Friday, October 15, 2021
    Time: 11:30 a.m. ET
  • Needham Virtual Biotech Private Company 1×1 Forum
    Format: 1×1 Meetings
    Date: Tuesday, October 19 – Wednesday, October 20, 2021

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

CONTACTS

Media:
Will Zasadny
Canale Communications, Inc.
will.zasadny@canalecomm.com
(619) 961-8848

Investors:
Sarah McCabe
Stern Investor Relations
sarah.mccabe@sternir.com
IR@recodetx.com